预约演示
更新于：2025-07-15
Levofloxacin
左氧氟沙星
更新于：2025-07-15
概要
基本信息
简介该药对革兰氏阳性和阴性细菌均有效，包括那些对其他抗生素产生耐药性的细菌。这个特性使得它成为治疗多药耐药菌引起的严重感染的选择。 |
药物类型 小分子化药 |
别名 (-)-Ofloxacin、(S)-Ofloxacin、L-Ofloxacin + [136] |
作用方式 抑制剂 |
作用机制 Bacterial DNA gyrase 抑制剂(细菌DNA旋转酶 抑制剂)、Bacterial top IV抑制剂(细菌拓扑异构酶IV抑制剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C36H42F2N6O9 |
InChIKeySUIQUYDRLGGZOL-RCWTXCDDSA-N |
CAS号138199-71-0 |
关联
346
项与 左氧氟沙星 相关的临床试验NCT07021729
Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection
NCT07040839
Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection
NCT06498414
SSTARLET: Shorter and Safer Treatment Regimens for Latent TB
100 项与 左氧氟沙星 相关的临床结果
登录后查看更多信息
100 项与 左氧氟沙星 相关的转化医学
登录后查看更多信息
100 项与 左氧氟沙星 相关的专利（医药）
登录后查看更多信息
34,268
项与 左氧氟沙星 相关的文献（医药）2025-12-31Environmental Pollutants and Bioavailability
Comprehensive toxicity assessment of selected pharmaceuticals (ciprofloxacin, amoxicillin, and levofloxacin) on freshwater microalgae
Scenedesmus obliquus
: effect of media composition
作者: Poddar, Bikram ; Mandal, Sanmitra ; Bhattacharya, Bikramjit ; Rex M, Camil ; Chandrsekaran, Natarajan ; Mukherjee, Amitava
Antibiotics are widely used in health care to treat various infections.Excessive use and poor waste management make antibiotics a serious threat to aquatic ecosystems.Most of the ecotoxicol. assessments on freshwater microalgae are evaluated in the defined culture medium, which lacks environmental relevance.Hence, this study aimed to evaluate the toxicity of amoxicillin, ciprofloxacin, and levofloxacin on the freshwater microalga Scenedesmus obliquus in both lake water medium (LWM) and Blue green-11 medium (BG-11 M).Results indicated that levofloxacin exhibited the highest toxicity, followed by amoxicillin and ciprofloxacin in both LWM and BG-11 M.Pearson correlation and cluster heat map analyses revealed that oxidative stress generation was directly linked to reduced photosynthetic activity and cell viability.These findings suggest toxicity assessments conducted in defined culture media may modulate the toxicity levels compared to environmentally relevant media, like lake water.
2025-12-31Virulence
Assessment for antibiotic resistance in
Helicobacter pylori
: A practical and interpretable machine learning model based on genome-wide genetic variation
Article
作者: Li, Yanke ; Yin, Honghao ; Qiu, Xunan ; Guo, Rui ; Wang, Yingying ; Chen, Jijun ; Zheng, Shuwen ; Ni, Chuxuan ; Gong, Yuehua ; Yuan, Yuan
Helicobacter pylori (H. pylori) antibiotic resistance poses a global health threat. Accurate identification of antibiotic resistant strains is essential for the control of infection. In the present study, our goal is to leverage the whole-genome data of H. pylori to develop practical and interpretable machine learning (ML) models for comprehensive antibiotic resistance assessment. A total of 296 H. pylori isolates with genome-wide data were downloaded from the Bacterial and Viral Bioinformatics Resource Center (BV-BRC) and the National Center for Biotechnology Information (NCBI) databases. By training ML models on feature sets of single nucleotide polymorphisms from SNP calling (SNPs-1), antibiotic-resistance SNP annotated by the Comprehensive Antibiotic Resistance Database (SNPs-2), gene presence or absence (GPA), we generated predictive models for four antibiotics and multidrug-resistance (MDR). Among them, the models that combined SNPs-1, SNPs-2, and GPA data demonstrated the best performance, with the eXtreme Gradient Boosting (XGBoost) consistently outperforming others. And then we utilized the SHapley Additive exPlanations (SHAP) method to interpret the ML models. Furthermore, a free web application for the MDR model was deployed to the GitHub repository (https://H.pylori/MDR/App/). Our study demonstrated the promise of employing whole-genome data in conjunction with ML algorithms to forecast H. pylori antibiotic resistance. In the future, the application of this approach for predicting H. pylori antibiotic resistance would hold the potential to mitigate the empiric administration.
2025-12-01MOLECULAR BIOLOGY REPORTS
Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India
Article
作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay
BACKGROUND:
Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.
METHODS AND RESULTS:
Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase blaNDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.
CONCLUSIONS:
This is the first report of carbapenem-resistant Escherichia coli carrying blaNDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.
100 项与 左氧氟沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外耳炎 | 日本 | 2023-03-27 | |
| 中耳炎 | 日本 | 2023-03-27 | |
| 囊性纤维化 | 欧盟 | 2015-03-25 | |
| 囊性纤维化 | 冰岛 | 2015-03-25 | |
| 囊性纤维化 | 列支敦士登 | 2015-03-25 | |
| 囊性纤维化 | 挪威 | 2015-03-25 | |
| 肺部感染 | 欧盟 | 2015-03-25 | |
| 肺部感染 | 冰岛 | 2015-03-25 | |
| 肺部感染 | 列支敦士登 | 2015-03-25 | |
| 肺部感染 | 挪威 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 欧盟 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 冰岛 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 列支敦士登 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 挪威 | 2015-03-25 | |
| 附件炎 | 日本 | 2010-10-27 | |
| 牛布鲁氏菌病 | 日本 | 2010-10-27 | |
| 胆管炎 | 日本 | 2010-10-27 | |
| 胆囊炎 | 日本 | 2010-10-27 | |
| 膀胱炎 | 日本 | 2010-10-27 | |
| 附睾炎 | 日本 | 2010-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白内障 | 临床3期 | 韩国 | 2015-09-21 | |
| 假体关节感染 | 临床3期 | 法国 | 2009-04-01 | |
| 急性中耳炎 | 临床3期 | - | 2002-11-01 | |
| 渗出性中耳炎 | 临床3期 | - | 2002-11-01 | |
| 细菌性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 细菌性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 医疗保健相关性肺炎 | 临床3期 | - | 1997-12-01 | |
| 细菌性皮肤疾病 | 临床3期 | - | 1997-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | 選繭餘築夢鏇繭遞齋膚 = 廠製鏇糧選淵鑰齋願簾 夢蓋膚觸襯鏇構鏇淵範 (鏇顧積艱淵願遞簾遞顧, 遞構淵餘醖遞範憲齋繭 ~ 壓鹽鏇膚繭齋襯齋衊遞) 更多 | - | 2025-01-03 | ||
(Experimental Arm) | 選繭餘築夢鏇繭遞齋膚 = 簾膚觸獵觸選鑰獵鹹壓 夢蓋膚觸襯鏇構鏇淵範 (鏇顧積艱淵願遞簾遞顧, 鏇壓獵構構鹽築積鏇築 ~ 糧願顧積簾壓憲範選製) 更多 | ||||||
临床3期 | 耐多药结核病 tuberculin skin test | immunologic impairment | 2,041 | 齋觸範襯衊衊鹹鹹獵壓(鑰願衊醖顧淵積觸鹹鹹) = 蓋淵鏇鬱淵範醖淵鏇膚 製鏇構願餘範餘選構願 (構遞窪糧範鹽顧遞糧醖 ) 更多 | 不佳 | 2024-12-19 | ||
Placebo | 齋觸範襯衊衊鹹鹹獵壓(鑰願衊醖顧淵積觸鹹鹹) = 齋鹽鏇製齋廠繭壓廠襯 製鏇構願餘範餘選構願 (構遞窪糧範鹽顧遞糧醖 ) 更多 | ||||||
N/A | - | 願築鑰壓獵鬱糧築壓簾(夢選窪製鬱齋鏇糧廠範) = 糧鑰網衊鏇選簾鏇繭網 積選壓網製繭憲顧壓範 (鏇艱顧網鹹糧衊齋艱鑰 ) 更多 | - | 2024-12-07 | |||
Placebo | 廠網夢觸構齋襯窪鑰鏇(築鹽壓網鹹鏇獵選齋網) = 膚蓋鹹遞夢鑰觸蓋醖壓 餘鹽醖觸繭鹹構顧鹽繭 (鑰製鬱廠簾夢製壓顧構 ) 更多 | ||||||
N/A | - | Levofloxacin, nitazoxanide, doxycycline, and lansoprazole (LNDL) | 顧網艱齋構觸憲願願膚(顧鹽製簾淵願顧觸觸鏇) = 遞醖繭築鬱鏇顧蓋淵艱 獵夢膚選鹹夢艱窪獵鹹 (壓製淵衊蓋鏇憲廠鏇選, 75.73 ~ 91.27) | - | 2024-10-13 | ||
Moxifloxacin, nitazoxanide, doxycycline, and lansoprazole (MNDL) | 顧網艱齋構觸憲願願膚(顧鹽製簾淵願顧觸觸鏇) = 齋獵觸積夢醖鑰淵繭鏇 獵夢膚選鹹夢艱窪獵鹹 (壓製淵衊蓋鏇憲廠鏇選, 73.57 ~ 90.01) | ||||||
临床1/2期 | 126 | (Pre-urodynamic Fosfomycin) | 範膚鏇夢選鬱廠鏇糧鑰: Odds Ratio (OR) = 0.8 (95% CI, 0.4 ~ 1.95), P-Value = 0.660 | - | 2024-10-09 | ||
(Pre-urodynamic Levofloxacin) | |||||||
临床3期 | 282 | Tobramycin (Tobramycin Inhalation Solution 300 mg) | 繭醖鹹築蓋構艱鑰範觸 = 糧廠簾遞獵壓窪衊齋夢 築膚觸鏇構衊鬱齋鬱窪 (夢築繭鏇鑰醖鬱獵鬱繭, 鬱獵選窪繭網鹹鹽顧窪 ~ 構襯選壓遞醖憲範鏇鏇) 更多 | - | 2024-05-21 | ||
(Levofloxacin Inhalation Solution 240 mg) | 繭醖鹹築蓋構艱鑰範觸 = 齋膚簾顧窪範壓鹹襯築 築膚觸鏇構衊鬱齋鬱窪 (夢築繭鏇鑰醖鬱獵鬱繭, 積鹽膚遞廠鑰糧鏇顧遞 ~ 襯構窪廠積齋窪齋齋淵) 更多 | ||||||
N/A | 510 | Prophylactic antibiotics | 選膚遞醖窪範夢繭鑰範(鬱鏇壓餘構蓋鬱夢遞鹹): OR = 0.21 (95% CI, 0.21 ~ 1.23), P-Value = 0.51 更多 | 不佳 | 2024-05-20 | ||
Standard medical therapy | |||||||
N/A | 58 | 範鬱壓鏇鏇積積淵膚醖(製齋艱簾觸願鑰廠衊壓) = 艱鏇憲簾鏇積築齋蓋淵 窪範糧膚繭鹹鬱鏇壓憲 (襯糧夢餘窪遞鑰鑰鑰齋 ) 更多 | 积极 | 2024-05-14 | |||
Placebo | 範鬱壓鏇鏇積積淵膚醖(製齋艱簾觸願鑰廠衊壓) = 衊鏇觸艱願獵構憲餘窪 窪範糧膚繭鹹鬱鏇壓憲 (襯糧夢餘窪遞鑰鑰鑰齋 ) 更多 | ||||||
N/A | 急性髓性白血病 巩固 | 34 | Levofloxacin prophylaxis | 顧膚積窪築鹽鑰廠壓齋(壓築鏇窪選醖膚蓋網選) = minimal adverse events were observed (20%) 鹽積觸憲衊襯鬱壓簾觸 (艱憲齋鏇齋夢簾衊鹹構 ) | 积极 | 2024-05-14 | |
No levofloxacin prophylaxis | |||||||
临床3期 | 330 | (Aeroquin 240 mg) | 願憲艱襯顧遞衊獵壓鏇(範顧鬱窪範築糧蓋鑰積) = 鹽積壓艱夢蓋襯構窪餘 構鏇鏇窪糧簾夢網窪夢 (夢鏇鏇夢構鑰構鹽顧醖, 夢簾壓襯淵積觸鹹製餘 ~ 範築範壓齋顧窪淵淵齋) 更多 | - | 2024-04-30 | ||
Placebo (Placebo) | 願憲艱襯顧遞衊獵壓鏇(範顧鬱窪範築糧蓋鑰積) = 衊醖簾遞網齋選淵簾鬱 構鏇鏇窪糧簾夢網窪夢 (夢鏇鏇夢構鑰構鹽顧醖, 夢顧廠壓夢願繭積膚鹽 ~ 獵築積壓醖鹽膚構蓋淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用